This hypothesis can be supported by the following evidence: 1) genetic or pharmacological induction of NOR1 expression induces apoptosis in aggressive lymphoma cells and results in reduced tumor growth in a xenograft model, 2) NOR1 is positively correlated with pro-apoptotic genes in primary aggressive lymphomas, and 3) overexpression of NOR1 leads to strong induction of pro-apoptotic genes, including p53 upregulated modulator of apoptosis (PUMA), TNF related apoptosis inducing ligand (TRAIL), Bid, and Bik (Deutschet al., 2017). The gene discussed is NR4A3; the disease is lymphoma.